AU2015212357B2 - Tolerogenic compositions comprising and uses thereof - Google Patents

Tolerogenic compositions comprising and uses thereof Download PDF

Info

Publication number
AU2015212357B2
AU2015212357B2 AU2015212357A AU2015212357A AU2015212357B2 AU 2015212357 B2 AU2015212357 B2 AU 2015212357B2 AU 2015212357 A AU2015212357 A AU 2015212357A AU 2015212357 A AU2015212357 A AU 2015212357A AU 2015212357 B2 AU2015212357 B2 AU 2015212357B2
Authority
AU
Australia
Prior art keywords
vac
pylori
allergen
polypeptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015212357A
Other languages
English (en)
Other versions
AU2015212357A1 (en
Inventor
Daniela ENGLER-ANDERS
Anne Mueller
Christian Taube
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universität
Leiden University Medical Center
Original Assignee
Zurich Universität
Leiden University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universität, Leiden University Medical Center filed Critical Zurich Universität
Publication of AU2015212357A1 publication Critical patent/AU2015212357A1/en
Application granted granted Critical
Publication of AU2015212357B2 publication Critical patent/AU2015212357B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2015212357A 2014-01-31 2015-01-30 Tolerogenic compositions comprising and uses thereof Active AU2015212357B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14153365.3A EP2902037A1 (en) 2014-01-31 2014-01-31 Tolerogenic compositions comprising and uses thereof
EP14153365.3 2014-01-31
PCT/IB2015/050703 WO2015114575A1 (en) 2014-01-31 2015-01-30 Tolerogenic compositions comprising and uses thereof

Publications (2)

Publication Number Publication Date
AU2015212357A1 AU2015212357A1 (en) 2016-08-18
AU2015212357B2 true AU2015212357B2 (en) 2020-05-28

Family

ID=50028895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015212357A Active AU2015212357B2 (en) 2014-01-31 2015-01-30 Tolerogenic compositions comprising and uses thereof

Country Status (8)

Country Link
US (1) US9999660B2 (enExample)
EP (2) EP2902037A1 (enExample)
JP (1) JP6563937B2 (enExample)
AU (1) AU2015212357B2 (enExample)
CA (1) CA2943149C (enExample)
DK (1) DK3099314T3 (enExample)
ES (1) ES2806773T3 (enExample)
WO (1) WO2015114575A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166986B2 (en) 2014-01-31 2021-11-09 Universitat Zurich Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN122580105A (zh) * 2023-09-26 2026-08-14 阿托皮亚治疗协会 用于预防或治疗过敏和炎症性疾病的药物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004017A2 (en) * 2000-07-07 2002-01-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for preparing oral vaccines
WO2003018054A1 (en) * 2001-08-31 2003-03-06 Chiron Srl. Helicobacter pylori vaccination
EP1582215A1 (en) * 2002-11-28 2005-10-05 Japan Science and Technology Agency Method of inhibiting cell death, cell death inhibitor and remedy for disease caused by cell death containing the cell death inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166986B2 (en) 2014-01-31 2021-11-09 Universitat Zurich Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004017A2 (en) * 2000-07-07 2002-01-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for preparing oral vaccines
WO2003018054A1 (en) * 2001-08-31 2003-03-06 Chiron Srl. Helicobacter pylori vaccination
EP1582215A1 (en) * 2002-11-28 2005-10-05 Japan Science and Technology Agency Method of inhibiting cell death, cell death inhibitor and remedy for disease caused by cell death containing the cell death inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OERTLI M. et al., "SI Materials and MethodsInduction and Analysis of Allergen-Induced Asthma", SUPPORTING INFORMATION, PNAS, 2013, vol. 110, no. 8, pages 1 - 7 *

Also Published As

Publication number Publication date
ES2806773T3 (es) 2021-02-18
US20170007683A1 (en) 2017-01-12
WO2015114575A1 (en) 2015-08-06
CA2943149C (en) 2022-07-12
JP6563937B2 (ja) 2019-08-21
DK3099314T3 (da) 2020-07-20
EP3099314B1 (en) 2020-04-22
AU2015212357A1 (en) 2016-08-18
US9999660B2 (en) 2018-06-19
EP3099314A1 (en) 2016-12-07
CA2943149A1 (en) 2015-08-06
JP2017509597A (ja) 2017-04-06
EP2902037A1 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
Kurup et al. Animal models of allergic bronchopulmonary aspergillosis
JP5191234B2 (ja) 免疫疾患の予防ないし治療剤および方法
EP3099314B1 (en) Tolerogenic compositions comprising and uses thereof
KR20130098110A (ko) 봉독-ｐｌａ2를 포함하는 이상 조절 ｔ 세포 활성 저하 관련 질환의 치료 또는 예방용 약학적 조성물
US20090176696A1 (en) Methods And Compositions For Modulating An Immune Response
Boyaka et al. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity
Macaubas et al. Respiratory tolerance in the protection against asthma
WO2014037717A1 (en) Compositions and methods relating to the treatment of diseases
US7846458B1 (en) Method and vaccine for treatment of pythiosis insidiosi in humans and lower animals
JP4966661B2 (ja) 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
WO2017125417A1 (en) Tofacitinib as vaccination immune modulator
JP7423523B2 (ja) ディフェンシンによる移植片対宿主病の予防と治療
US11166986B2 (en) Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease
US20070190078A1 (en) Filamentous haemagglutinin in the treatment and/or prophylaxis of immune-mediated disorders
JPWO1999040935A1 (ja) 新規な免疫異常性疾患予防・治療用剤
JP2015506975A (ja) 家畜の非ヒト哺乳動物における炎症性疾患の予防
RU2318872C2 (ru) Рекомбинантные штаммы вируса гриппа, экспрессирующие микобактериальный протективный антиген esat-6, и их использование для профилактики и лечения туберкулеза
WO2013134656A1 (en) Induction of th17 immune response
CN114903973B (zh) 一种呼吸道粘膜免疫增强药物组合物
Zhang Research progress on the role of immune cells in Brucella infection
US9289485B2 (en) Therapeutic application of S. pyogenes C-terminal peptide
EP4669337A1 (en) USEFUL AGENTS FOR THE PREVENTION OR TREATMENT OF ALLERGIC AND INFAMMATORY DISORDERS
ORAL Mucosal tolerance and autoimmunity
WO2006109285A1 (en) Methods and compounds for the treatment of autoimmune diseases and chronic inflammatory conditions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)